Omar Ali
member of the NICE Adoption & Impact Reference Panel; visiting lecturer on value-based pricing and innovative contracting, University of Portsmouth
Guidelines in Practice editorial advisory consultant for Value-based prescribing
View from the groundIs the NHS paying too much for new medicines?
Triggered by research carried out by the University of York, the BBC and other national media were recently reporting that the cancer drugs fund is poor value for money. The research in question stated that NICE has set its price threshold too high, critically stating that the cost per quality ...
